# Tissue factor expression

Source: https://onco.cc/biomarkers/tissue-factor-expression/  
OnCo record `tissue-factor-expression` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tissue factor, the clotting trigger, is overexpressed on cervical and several other cancers. Tisotumab vedotin is labelled for cervical cancer without a tissue factor test.

## Summary

Tisotumab vedotin (Tivdak) is a tissue factor-directed ADC labelled for recurrent or metastatic cervical cancer after chemotherapy (innovaTV 301); the label names tissue factor only as the target and no expression threshold was used in the trials. Its ocular toxicity mirrors mirvetuximab's and requires the same eye care.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: tissue factor; TF expression; F3 expression; tissue factor positive
- Tags: biomarker; surface-antigen; no-threshold

## Sources

- TIVDAK prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9fe3f32-4219-466e-acb9-3f609b4f4df1

## Connected records

- biomarkers: [Folate receptor alpha expression (FRα-positive, PS2+ >= 75%)](https://onco.cc/biomarkers/folr1-expression/), [PD-L1 CPS (combined positive score)](https://onco.cc/biomarkers/pd-l1-cps/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Recurrent or metastatic cervical cancer](https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/)
- drugs: [Tisotumab vedotin](https://onco.cc/drugs/tisotumab-vedotin/)
- targets: [Tissue factor](https://onco.cc/targets/tissue-factor/)

---
JSON: https://onco.cc/api/v1/entities/tissue-factor-expression.json